GlassScriptPhysician profile
David R Goldstein
NPI 1639141815
$2,002.76
in general payments reported to CMS, 2019-2025
35 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $72.30 · 2021: $113 · 2022: $175 · 2023: $436 · 2024: $359 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.78 | 2019-2023 | |
| Astellas Pharma US INC | $161.87 | 2022-2024 | Veozah |
| Genentech USA, INC. | $150.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $123.04 | 2019 | |
| Myriad Women'S Health, INC. | $101.37 | 2023 | Myrisk |
| Pfizer INC. | $84.63 | 2022-2024 | |
| Hologic Sales and Service, LLC | $84.61 | 2019-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Exeltis, USA INC. | $82.13 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $71.63 | 2019-2022 | |
| Sage Therapeutics, LLC | $65.32 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $63.63 | 2022-2024 | Wegovy |
| Shield Therapeutics INC | $60.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.88 | 2023 | |
| Evofem Biosciences, INC. | $55.34 | 2021-2022 | |
| Lilly USA, LLC | $52.44 | 2023-2025 | Jardiance, Zepbound |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $50.56 | 2025 | |
| Sumitomo Pharma America, INC. | $47.60 | 2024-2025 | Myfembree |
| Lupin INC. | $44.31 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.83 | 2019-2022 | |
| Exact Sciences Corporation | $40.39 | 2024-2025 | Cologuard Collection Kit |
| Davol INC. | $37.33 | 2021 | |
| Coopersurgical, INC. | $37.23 | 2024-2025 | Paragard T 380a |
| Aspira Women'S Health INC | $33.81 | 2022 | |
| Mimedx Group, INC. | $32.34 | 2025 | |
| Meditrina | $31.52 | 2021-2025 | |
| Smith+Nephew, INC. | $25.76 | 2025 | Stravix Pl |
| Myovant Sciences INC. | $24.00 | 2022 | |
| Merck Sharp & Dohme LLC | $19.05 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.67 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.98 | 2024 | Voquezna |
| Myriad Genetic Laboratories, INC. | $15.48 | 2024 | Myrisk |
| Provepharm INC. | $14.96 | 2025 | Bludigo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2023 | Xifaxan |
| Amgen INC. | $12.75 | 2022 | |
| Avion Pharmaceuticals | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.